Top

Open Access 01-11-2020 | Prostate Cancer | Original Article

Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany

Authors: Ingo Diel, Sonja Ansorge, David Hohmann, Christina Giannopoulou, Daniela Niepel, Michele Intorcia

Published in: Supportive Care in Cancer | Issue 11/2020

Abstract

Purpose

Bisphosphonates and denosumab prevent bone complications in patients with bone metastases from solid tumours. This retrospective, longitudinal, cohort study provides data on their real-world use in this setting in Germany.

Methods

Adults with bone metastases from breast, prostate or lung cancer who were newly initiated on a bisphosphonate or denosumab between 1 July 2011 and 31 December 2015 were identified from a German healthcare insurance claims database. Primary outcomes included persistence, compliance, discontinuation and switch rates at 12 months.

Results

This study included 1130 patients with bone metastases: 555 (49%) had breast cancer, 361 (32%) prostate cancer and 242 (21%) lung cancer. Mean age was 65 years for patients with breast or lung cancer and 74 years for those with prostate cancer. Across all tumour types, compared with any bisphosphonate, 12-month persistence was higher with denosumab (breast cancer 78% vs 54–58%, prostate cancer 58% vs 50%, lung cancer 68% vs 34–60%), median time to discontinuation was longer with denosumab and switch rates were lower for denosumab (breast cancer 5% vs 14–19%, prostate cancer 2% vs 11%, lung cancer 3% vs 7–12%). Compliance at 12 months was longer for denosumab than for any bisphosphonate in breast cancer (75% vs 42–48%) and in prostate cancer (47% vs 36%).

Conclusions

Patients initiated on denosumab following a diagnosis of bone metastases from breast, prostate or lung cancer had greater medication persistence, longer time to discontinuation, improved compliance and lower switch rates than those initiated on a bisphosphonate.

Available only for authorised users

Body JJ, Quinn G, Talbot S, Booth E, Demonty G, Taylor A, Amelio J (2017) Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases. Crit Rev Oncol Hematol 115:67–80. https://doi.org/10.1016/j.critrevonc.2017.04.008CrossRefPubMed

Suva LJ, Washam C, Nicholas RW, Griffin RJ (2011) Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol 7(4):208–218. https://doi.org/10.1038/nrendo.2010.227CrossRefPubMedPubMedCentral

Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall’Oglio M, Franzén L, Coleman R, Vogelzang NJ, O’Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213–223. https://doi.org/10.1056/NEJMoa1213755CrossRefPubMed

Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 9(Suppl 4):14–27. https://doi.org/10.1634/theoncologist.9-90004-14CrossRefPubMed

Coleman R, Body J, Aapro M, Hadji P, Herrstedt J (2014) Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 25(suppl_3):iii124–iii137CrossRef

von Moos R, Body JJ, Egerdie B, Stopeck A, Brown J, Fallowfield L, Patrick DL, Cleeland C, Damyanov D, Palazzo FS, Marx G, Zhou Y, Braun A, Balakumaran A, Qian Y (2016) Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. Support Care Cancer 24(3):1327–1337. https://doi.org/10.1007/s00520-015-2908-1CrossRef

Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT (2010) Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 184(1):162–167. https://doi.org/10.1016/j.juro.2010.03.034CrossRefPubMed

Yong M, Jensen AO, Jacobsen JB, Norgaard M, Fryzek JP, Sorensen HT (2011) Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007). Breast Cancer Res Treat 129(2):495–503. https://doi.org/10.1007/s10549-011-1475-5CrossRefPubMed

Pereira J, Body JJ, Gunther O, Sleeboom H, Hechmati G, Maniadakis N, Terpos E, Acklin YP, Finek J, von Moos R (2016) Cost of skeletal complications from bone metastases in six European countries. J Med Econ 19(6):611–618. https://doi.org/10.3111/13696998.2016.1150852CrossRefPubMed

10.

Hatoum HT, Lin S-J, Smith MR, Guo A, Lipton A (2011) Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis. Clin Breast Cancer 11(3):177–183CrossRef

11.

Jensen AO, Jacobsen JB, Norgaard M, Yong M, Fryzek JP, Sorensen HT (2011) Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer 11:29. https://doi.org/10.1186/1471-2407-11-29CrossRefPubMedPubMedCentral

12.

Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar R, Litsas G, McKay R, Podoloff DA, Srinivas S (2013) NCCN task force report: bone health in cancer care. J Natl Compr Cance Netw 11(suppl 3):S1–S50CrossRef

13.

Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, Shapiro CL, Shields A, Smith MR, Srinivas S (2009) NCCN task force report: bone health in cancer care. J Natl Compr Cance Netw 7(Suppl 3):S1–S32

14.

European Medicines Agency (2018) Zometa (zoledronic acid for injection). Summary of product characteristics. https://www.ema.europa.eu/documents/product-information/zometa-epar-product-information_en.pdf. Accessed 30 Jan 2020

15.

European Medicines Agency (2018) XGEVA (denosumab). Summary of product characteristics. https://www.ema.europa.eu/documents/product-information/xgeva-epar-product-information_en.pdf. Accessed 30 Jan 2020

16.

European Medicines Agency (2018) Bondronat (ibandronic acid): summary of product characteristics. https://www.ema.europa.eu/documents/product-information/bondronat-epar-product-information_en.pdf. Accessed 30 Jan 2020

17.

Medicines.org (2017) Pamidronate disodium 9 mg/ml sterile concentrate. https://www.medicines.org.uk/emc/medicine/21443. Accessed 30 Jan 2020

18.

Medicines.org (2017) Bonefos capsules. https://www.medicines.org.uk/emc/product/899/smpc. Accessed 30 Jan 2020

19.

Roelofs J, Thompson K, Ebetino H, Rogers J, Coxon P (2010) Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des 16(27):2950–2960CrossRef

20.

Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83(9):1032–1045. https://doi.org/10.4065/83.9.1032CrossRefPubMedPubMedCentral

21.

Brown JE, Coleman RE (2012) Denosumab in patients with cancer—a surgical strike against the osteoclast. Nat Rev Clin Oncol 9(2):110–118CrossRef

22.

Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18(2):75–85CrossRef

23.

Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48(16):3082–3092. https://doi.org/10.1016/j.ejca.2012.08.002CrossRefPubMed

24.

Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94(19):1458–1468CrossRef

25.

Zhang Z, Pu F, Shao Z (2017) The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: a meta-analysis of randomized controlled trials. J Bone Oncol 9:21–24. https://doi.org/10.1016/j.jbo.2017.09.003CrossRefPubMedPubMedCentral

26.

Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35):5132–5139. https://doi.org/10.1200/jco.2010.29.7101CrossRefPubMed

27.

Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768):813–822. https://doi.org/10.1016/s0140-6736(10)62344-6CrossRefPubMedPubMedCentral

28.

Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29(9):1125–1132. https://doi.org/10.1200/jco.2010.31.3304CrossRefPubMed

29.

Von Moos R, Body J, Egerdie B, Stopeck A, Brown JE, Damyanov D, Fallowfield LJ, Marx G, Cleeland CS, Patrick DL (2013) Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer 21(12):3497–3507CrossRef

30.

Wong GW, Miravitlles M, Chisholm A, Krishnan JA (2014) Respiratory guidelines—which real world? Ann Am Thorac Soc 11(Supplement 2):S85–S91CrossRef

31.

Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353(5):487–497CrossRef

32.

Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11(1):44–47. https://doi.org/10.1111/j.1524-4733.2007.00213.xCrossRefPubMed

33.

Hernandez RK, Quigley J, Pirolli M, Quach D, Chen KS, Arellano J, Liede A (2014) Patients with bone metastases from solid tumors initiating treatment with a bone-targeted agent in 2011: a descriptive analysis using oncology clinic data in the US. Support Care Cancer 22(10):2697–2705CrossRef

34.

Qian Y, Bhowmik D, Kachru N, Hernandez RK (2017) Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States. Support Care Cancer 25(6):1845–1851CrossRef

35.

Arellano J, Hauber AB, Mohamed AF, Gonzalez JM, Collins H, Hechmati G, Gatta F, Qian Y (2015) Physicians’ preferences for bone metastases drug therapy in the United States. Value Health 18(1):78–83CrossRef

36.

Hechmati G, Hauber AB, Arellano J, Mohamed AF, Qian Y, Gatta F, Haynes I, Bahl A, von Moos R, Body J-J (2015) Patients’ preferences for bone metastases treatments in France, Germany and the United Kingdom. Support Care Cancer 23(1):21–28CrossRef

37.

Mortimer JE, Pal SK (2010) Safety considerations for use of bone-targeted agents in patients with cancer. Semin Oncol 37:S66–S72CrossRef

38.

Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O’Connor T, Velasco MR Jr, Weckstein D, O’Mara A, Loprinzi CL, Shapiro CL (2017) Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. Jama 317(1):48–58. https://doi.org/10.1001/jama.2016.19425CrossRefPubMedPubMedCentral

39.

Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, Haley BB, Sauter N, Mohanlal R, Zheng M, Lipton A (2017) Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial. JAMA Oncol 3(7):906–912. https://doi.org/10.1001/jamaoncol.2016.6316CrossRefPubMedPubMedCentral

40.

von Moos R, Body J-J, Rider A, de Courcy J, Bhowmik D, Gatta F, Hechmati G, Qian Y (2018) Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries. J Bone Oncol 11:1–9. https://doi.org/10.1016/j.jbo.2017.11.004CrossRef

Title: Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany
Authors: Ingo Diel
Sonja Ansorge
David Hohmann
Christina Giannopoulou
Daniela Niepel
Michele Intorcia
Publication date: 01-11-2020
Publisher: Springer Berlin Heidelberg
Keywords: Prostate Cancer
Lung Cancer
Metastasis
Bisphosphonate
Lung Cancer
Breast Cancer
Prostate Cancer
Breast Cancer
Bone Metastasis
Lung Cancer
Denosumab
Denosumab
Zoledronic Acid
Ibandronate
Published in: Supportive Care in Cancer / Issue 11/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-020-05357-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine